

ASX Announcement: 10 September 2026 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX: OIL)

Significant Milestone Reached in ACL Digital Pathology Study

The study with Australian Clinical Labs evaluating Optiscan's InForm™ platform in a live pathology setting has now successfully imaged more than 80 cases across a range of tissue types, cancers, and use cases.

HIGHLIGHTS

- Optiscan has successfully imaged more than 80 cases in its digital pathology study with Australian Clinical Labs (ACL).
- The study is using Optiscan's InForm™ to undertake real-time, slide-free cellular imaging at the point of contact, in a real-world pathology environment.
- As part of the study, InForm™ is being evaluated within ACL's flagship anatomical pathology laboratory in Western Australia.
- The collaboration is generating real-world pathology data to support workflow optimisation, pathologist training, and future regulatory submissions.
- By leveraging ACL's large pathology network, Optiscan is able to validate the technology across a diverse range of tissue types, cancers, and clinical use cases.



Figure 1: Optiscan's InForm™ device with members of the Optiscan team.

Optiscan Imaging Limited (ASX:OIL) (**'Optiscan'** or the **'Company'**) is pleased to announce significant progress in its clinical study with Australian Clinical Labs (**'ACL'**), with more than 80 cases successfully imaged using Optiscan's InForm™ digital pathology imaging device. This study forms part of the Company's Collaboration Agreement with ACL (see ASX announcement dated 10 November 2025) and is evaluating the performance of InForm™ in a high throughput pathology environment across a range of tissue types and use cases.

REAL-WORLD CLINICAL VALIDATION

To date, Optiscan has successfully imaged 84 cases at ACL's flagship pathology facility in Western Australia, providing an opportunity for real-world assessment of InForm™ in a high-volume clinical pathology setting. The cases assessed to date span a broad range of human tissue samples across multiple systems (including breast, head and neck, gastrointestinal, urinary, reproductive, respiratory, cardiovascular, endocrine, kidney, liver, prostate, eye, and skin), and pathologies (normal, benign, inflammatory, premalignant, and malignant), enabling Optiscan to evaluate the imaging performance of InForm™ under a broad spectrum of real-world clinical conditions in multiple replicates.

As part of the study, InForm™ is being used to image tissue specimens processed through ACL's centralised anatomical pathology laboratory in Western Australia. As samples from different organs and disease states move through the laboratory, the device captures digital, cellular-level images in real-time that pathologists can evaluate against conventional pathology methods such as standard haematoxylin and eosin (H&E)-stained glass slides to assess image quality and clinical performance.

Conventional Pathology	Pathology with Optiscan InForm™
Tissue removed	Tissue removed
Tissue processing (hours-days)	Real-time cellular imaging (0-5 minutes)
Glass slides prepared	Slide-free digital images
Microscopic review	Immediate digital review
Diagnosis	Diagnosis and permanent digital dataset

Figure 2: Conventional pathology workflow compared to digital pathology workflow with Optiscan InForm™.

PARTNERING FOR CLINICAL IMPACT

ACL is one of Australia's leading pathology providers, operating a nationwide network of over 40 National Association of Testing Authorities (NATA)-accredited laboratories, employing over 60 Royal

College of Pathologists of Australia (RCPA)-accredited pathologists and more than 4500 scientific, collection and support personnel, and servicing clinicians and patients through 1,273 collection centres. As one of the country's largest providers of hospital-based pathology services, ACL offers Optiscan access to an established pathology ecosystem capable of accelerating validation activities and refining how InForm™ integrates into existing laboratory workflows.

By imaging a diverse range of tissue types and pathological presentations, Optiscan will generate a comprehensive library of digital pathology images that can be used to refine imaging protocols, support pathologist training, and satisfy future regulatory submissions.

The collaboration also enables Optiscan to evaluate InForm™ under routine clinical laboratory conditions, providing valuable insights into device performance and workflow integration within an active pathology setting. These real-world findings will help optimise the platform for routine clinical use and strengthen its readiness for broader commercial deployment.




Figure 3: Current standard pathology workflow compared to real-time imaging with Optiscan InForm™.

STRATEGIC SIGNIFICANCE

Passing the 80 case milestone represents an important step in Optiscan's strategy to establish Optiscan InForm™ within leading clinical pathology environments. By working alongside one of Australia's largest pathology providers, Optiscan is able to evaluate the platform under routine laboratory conditions, refine its performance with direct input from pathologists, and generate clinical evidence that supports future product development. The program also expands Optiscan's understanding of how the InForm™

technology platform can be applied across a broader range of tissue types and pathology workflows, strengthening the platform's long-term scalability and commercial appeal.

REGULATORY SIGNIFICANCE

Generating real-world imaging data from the 84 cases collected thus far across a diverse range of human tissue samples, provides an important evidence base to support future regulatory submissions in Australia and the United States. In addition to demonstrating device performance across multiple tissue types, cancers, and use cases, the program is helping establish imaging protocols, validation datasets and pathologist training materials that are expected to form part of Optiscan's broader regulatory and clinical rollout strategy.



Figure 4: FDA milestone progress for Optiscan InForm™.

COMMERCIAL SIGNIFICANCE

Demonstrating how InForm™ performs within an active anatomical pathology laboratory provides the Company with the opportunity to optimise the platform for routine clinical use before commercial rollout. Demonstrating seamless integration into existing pathology workflows, while generating feedback from end users, helps strengthen the platform's value proposition for pathology providers and hospital laboratories. The collaboration has also established a reference site with a leading pathology organisation, which will provide critical support to future commercial discussions, and position Optiscan for broader adoption of its digital pathology technologies.

CEO COMMENT

Optiscan CEO and Managing Director, Dr Camile Farah, said:

“Successfully imaging more than 80 cases through the ACL study since deploying the device at the pathology group’s flagship Perth lab just over six months ago is an incredible achievement. This milestone doesn’t just demonstrate the maturity and commercial readiness of our InForm™ platform. It also highlights the potential impact real-time cellular imaging can have in transforming pathology.”

"Results to date from the ACL study have materially advanced the clinical validation of our technology, particularly in terms of evaluating how InForm™ performs across a range of tissue types and disease settings. InForm™ has been able to generate high resolution images of all soft tissue cancer types evident in the study's first 84 cases, recapitulating standard H&E-stained glass slide detail. For us, this isn't just about testing a device, it's about understanding how the technology may perform in the hands of pathologists and pathology technicians during their everyday work. That feedback is invaluable as we continue to refine the InForm™ workflow and prepare it for its wider clinical rollout."

"It has been a pleasure working alongside ACL, one of Australia's leading pathology providers, in the delivery of this study. It is allowing us to refine the way our technology may be used with direct input from end users, all while generating the clinical evidence needed to support our planned regulatory and commercial milestones."

"Digital pathology is rapidly reshaping the way tissue is analysed, and the collaboration with ACL gives Optiscan the opportunity to be part of this process. Results to date showcase how real-time, slide-free microscopic imaging can complement existing pathology workflows. The study is helping Optiscan deliver a key component of its overall development strategy, which is to make digital pathology more accessible, efficient and clinically useful."

ACL COLLABORATOR COMMENT

ACL Clinical Director, Dr Marissa Muller said:

"Reaching more than 80 cases in this study marks an important milestone in our collaboration with Optiscan and reflects ACL's commitment to innovation that has the potential to deliver meaningful benefits for patients, pathologists and laboratory teams."

"Having InForm™ operating within our anatomical pathology laboratory provides a unique opportunity to evaluate real-time, slide-free cellular imaging in a genuine clinical environment. Importantly, our pathologists and laboratory scientists are able to assess the technology across a diverse range of tissue types and clinical scenarios, while providing direct feedback on its potential integration into everyday pathology workflows."

"At ACL, our focus is always on delivering accurate, timely and high-quality diagnoses for every patient, every sample, every time. Collaborations such as this allow us to explore innovative technologies while maintaining that focus and ensuring that any advances we adopt are clinically meaningful, practical and ultimately contribute to better patient care."

"We are proud to be working alongside Optiscan and look forward to continuing to contribute our clinical and laboratory expertise as the technology progresses towards broader clinical application."

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: ceo@optiscan.com

Media & Investor Enquiries

The Capital Network

Julia Maguire

T: +61 2 7257 7338

E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit www.optiscan.com or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

About Australian Clinical Labs

Australian Clinical Labs (ACL) is a leading Australian private provider of pathology services. ACL is one of the largest private hospital pathology businesses nationally and in its established regions of Western Australia, Victoria, New South Wales, Queensland, South Australia and the Northern Territory, has an equivalent market position in community pathology to Sonic Healthcare and Healius. ACL also has a growing presence in the Australian Capital Territory. ACL has a national footprint of 1,273 approved collection centres and 28 clinics to collect patient samples and operates over 40 NATA accredited laboratories across Australia.

To learn more about ACL, visit www.clinicallabs.com.au

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.